Business of Cannabis: Cannabis News | Cannabis Views | Cannabis Trends

In this special edition of the Business of Cannabis Podcast, we go From Anecdote to Evidence with Dr Anne Katrin Schlag, Head of Research at Drug Science, and Graham Woodward, Chief Operating Officer at Releaf. Together, they explore how the UK can move from anecdotal patient stories to robust, real-world evidence — and why this shift is vital for expanding safe, trusted access to cannabis-based medicines. They unpack how clinics like Releaf are investing in quality-of-life surveys and data-driven patient care, what this means for regulators like NICE, and whether more solid evidence can finally open doors with the BMA, Royal Colleges and wider healthcare system. For anyone interested in how data and patient outcomes can unlock the next stage of UK medical cannabis, this is a conversation not to miss.

The third in our series of guest episodes features a discussion between CEO of Releaf, Tim Kirby, and Robert Jappie, Partner Fieldfisher’s Regulatory Group. Tim and Robert discuss Together, they explore the disconnect between the UK’s 2018 rescheduling of medical cannabis and the lack of meaningful access for patients today. Robert outlines the legal and regulatory hurdles that continue to obstruct progress, while Tim highlights the everyday impact these roadblocks have on clinics and patients. The episode also delves into the rise of self-medication and the persistent use of illicit sources. Tim and Robert examine the factors behind this trend, from affordability and education to stigma and patient trust, despite the existence of a legal framework. Finally, they unpack the complex compliance landscape for cannabis clinics in the UK. From advertising restrictions to tight prescribing protocols, the conversation reveals how clinics like Releaf build patient trust while navigating a shifting and often restrictive regulatory environment.

The second in our series of guest episodes features a discussion between CEO of Releaf, Tim Kirby, and James Duckenfield, CEO of Glass Pharms. Tim & James discuss the challenges and progress within the UK's medical cannabis industry since its legalisation in 2018, highlighting the previous stagnation due to various factors including inconsistent supply chains and a lack of a healthcare-focused approach. The discussion emphasises the importance of quality, consistency, and patient outcomes, showcasing how their collaboration aims to provide reliable medical cannabis to patients. They also touch upon the regulatory landscape, the need for better education for doctors, and the potential for significant growth in the UK market by addressing unmet healthcare needs.

Business of Cannabis: Podcast | E14 🎙   Next up we're speaking with Simone Van Breda, Chairman of the Union of Coffeeshop Retailers. Simone is the chairman of the Union of Coffeeshop Retailers in the #Netherlands, working at the national and international level to advance regulation of cannabis and to professionalise the emerging industry. She is one of the key figures who advocates legalisation on a #European level. Join us as our host Shahbaaz Kara-Virani chats with Simone about the future of cannabis and the Netherlands Cannabis Europa 2024.

Next up we have a special episode with Tim Kirby, Chief Executive Officer with Releaf and Michael Sassano, CEO and Chairman of the Board with SOMAÍ Pharmaceuticals.